This marks a key milestone in the company’s modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity, it states.

The EUR ~100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions.

The expansion, first announced in January 2025, is a central component of PolyPeptide’s mid-term strategy to meet rising global demand for peptide production. The EUR ~100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning.

“The Malmö expansion is a cornerstone of our mid-term growth strategy,” says Juan José González, CEO of PolyPeptide Group AG. “By leveraging modular construction and advanced automation, we’re accelerating capacity expansion to meet rising demand from key customers. This investment not only strengthens our position in the peptide CDMO market but also supports our ambition to double 2023 revenue by 2028 and deliver sustainable value to shareholders.”

The additional capacity will primarily support one of PolyPeptide’s large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028.